10月13日，Natera盘中下跌3.18%，报387.98美元/股，成交额1.46亿美元。消息面上，摩根士丹利将Natera目标价从355美元上调至435美元并维持增持评级，但股价在近期连续上涨后出现获利回吐。
近期Natera在多癌早期检测领域取得进展，其多癌筛查检测获FDA突破性设备认定，Signatera测试也在日本获批用于膀胱癌伴随诊断，公司临床管线持续扩张。尽管投行目标价上调反映对长期基本面的看好，但短期内市场情绪受生物科技板块整体走弱影响，Moderna下跌4.58%，行业回调压力明显。
（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.